Varicella zoster virus vaccine - Changchun BCHT Biotechnology
Alternative Names: Herpes Zoster Vaccine - Changchun BCHT Biotechnology; Shingles Vaccine - Changchun BCHT BiotechnologyLatest Information Update: 10 Feb 2026
At a glance
- Originator Changchun BCHT Biotechnology
- Class Varicella vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Herpes zoster; Varicella zoster virus infections
Most Recent Events
- 10 Feb 2026 Launched for Herpes zoster (Prevention) in China (SC) prior to February 2026 (Changchun BCHT Biotechnology pipeline, February 2026)
- 01 Feb 2023 Registered for Herpes zoster (Prevention) in China (SC)
- 18 Jul 2021 Changchun BCHT Biotechnology completes a phase III trial in Herpes zoster (Prevention) in China in July 2021(NCT04334577)